NewEdge Advisors’s Filana Therapeutics FLNA Stock Holding History

NewEdge Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.58K	Sell	3,300 -725	-18%	-$1.49K	﹤0.01%	3561
2025 Q4	$7.97K	Sell	4,025 -300	-7%	-$960	﹤0.01%	3533
2025 Q3	$12.6K	Hold	4,325	–	–	﹤0.01%	3262
2025 Q2	$7.83K	Hold	4,325	–	–	﹤0.01%	3277
2025 Q1	$6.49K	Buy	4,325 +1,750	+68%	+$4.42K	﹤0.01%	3226
2024 Q4	$6.08K	Buy	2,575 +2,075	+415%	+$36.4K	﹤0.01%	3177
2024 Q3	$14.7K	Hold	500	–	–	﹤0.01%	2822
2024 Q2	$6.18K	Buy	500 +300	+150%	+$6.32K	﹤0.01%	3021
2024 Q1	$4.06K	Buy	200 +150	+300%	+$3.46K	﹤0.01%	3206
2023 Q4	$1.13K	Hold	50	–	–	﹤0.01%	3446
2023 Q3	$832	Hold	50	–	–	﹤0.01%	3195
2023 Q2	$1.23K	Sell	50 -400	-89%	-$9.63K	﹤0.01%	3209
2023 Q1	$10.9K	Hold	450	–	–	﹤0.01%	2540
2022 Q4	$13	Buy	+450	New	+$16.2K	﹤0.01%	3671

Other funds holding FLNA

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

NewEdge Advisors's FLNA Position: Q1 2026 in Review

NewEdge Advisors reduced its Filana Therapeutics (FLNA) stake by 18% in Q1 2026, selling an estimated $1.49K and leaving 3,300 shares worth $5.58K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

NewEdge Advisors first reported a position in FLNA in Q4 2022 and has held it in 14 quarters since. The position peaked at $14.7K in Q3 2024. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

NewEdge Advisors held 3,300 shares of Filana Therapeutics worth $5.58K as of Q1 2026.
NewEdge Advisors sold 725 Filana Therapeutics shares in Q1 2026, an estimated $1.49K.
Filana Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3561 holding.
NewEdge Advisors first reported a position in Filana Therapeutics in Q4 2022 and has held it in 14 quarters since.
NewEdge Advisors's Filana Therapeutics position peaked at $14.7K in Q3 2024.
101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.